Patient-reported outcomes of patients with advanced renal cell carcinoma treated with nivolumab plus ipilimumab versus sunitinib (CheckMate 214): a randomised, phase 3 trial
Explore this paper's citation graph
Summary
This study aimed to assess whether health-related quality of life (HRQoL) could be used to further describe the benefit-risk profile of nivolumab plus ipilimumab versus sunitinib in patients with intermediate or poor risk, previously untreated, advanced renal cell carcinoma.
- Type
- article
- Published
- 2019-01-15
- Cited by
- 204
- References
- 33
- Access
- Open access
- OpenAlex
- https://openalex.org/W2909056931
- Semantic Scholar
- https://api.semanticscholar.org/CorpusID:58596538
Keywords
Medicine, Nivolumab, Ipilimumab, Sunitinib, Renal cell carcinoma
References
- Design and analysis of quality of life studies in clinical trials
- Clinical Trials with Missing Data: A Guide for Practitioners
- Development and validation of a scale to measure disease-related symptoms of kidney cancer.
- Development and initial validation of the NCCN/FACT symptom index for advanced kidney cancer.
- Combining Distribution- and Anchor-Based Approaches to Determine Minimally Important Differences
- Modeling valuations for EuroQol health states.
- Patient-reported outcomes for axitinib vs sorafenib in metastatic renal cell carcinoma: phase III (AXIS) trial
- Early change in patient-reported health during lung cancer chemotherapy predicts clinical outcomes beyond those predicted by baseline report: results from Eastern Cooperative Oncology Group Study 5592.
- Quality of life and survival in advanced cervical cancer: a Gynecologic Oncology Group study.
- A Comparison of the Renal Cell Carcinoma Symptom Index (RCC-SI) and the Functional Assessment of Cancer Therapy –Kidney Symptom Index (FKSI)
- Prognostic factors for overall survival in patients with metastatic renal cell carcinoma treated with vascular endothelial growth factor-targeted agents: results from a large, multicenter study.
- The Functional Assessment of Cancer Therapy scale: development and validation of the general measure.
- Patient-reported outcomes in a phase III, randomized study of sunitinib versus interferon-α as first-line systemic therapy for patients with metastatic renal cell carcinoma in a European population
- External validation and comparison with other models of the International Metastatic Renal-Cell Carcinoma Database Consortium prognostic model: a population-based study
- Pazopanib versus sunitinib in metastatic renal-cell carcinoma.
- The EQ-5D—a generic quality of life measure—is a useful instrument to measure quality of life in patients with Parkinson's disease
- Sunitinib versus interferon alfa in metastatic renal-cell carcinoma.
- Beyond traditional outcomes: improving quality of life in patients with renal cell carcinoma.
- Pazopanib in Locally Advanced or Metastatic Renal Cell Carcinoma: Results of a Randomized Phase III Trial
- Nivolumab versus Everolimus in Advanced Renal Cell Carcinoma
Cited by
- Renal cell carcinoma
- Targeted therapy for metastatic renal cell carcinoma.
- Current and emerging therapies for first-line treatment of metastatic clear cell renal cell carcinoma.
- CheckMate 214 patient-reported outcomes: listening to our patients.
- Patient-reported Outcome Measures in Metastatic Urinary Cancers.
- Differential Expression of the T cell Inhibitor TIGIT in Glioblastoma and Multiple Sclerosis
- Systemtherapie des Nierenzellkarzinoms
- Strategies to Improve Cancer Immune Checkpoint Inhibitors Efficacy, Other Than Abscopal Effect: A Systematic Review
- Immune checkpoint inhibitors and neuropathy: A new dawn.
- Understanding and overcoming the resistance of cancer to PD-1/PD-L1 blockade.
- The role of metastasectomy in advanced renal cell carcinoma
- Many Elderly Patients With Stage IV Metastatic Renal Cell Carcinoma May Benefit From More-Aggressive Treatment.
- Combination of CTLA-4 and PD-1 blockers for treatment of cancer
- ANGPTL3 inhibits renal cell carcinoma metastasis by inhibiting VASP phosphorylation.
- Long-Term Control of Metastatic Renal Cell Carcinoma Using Pazopanib
- Should we use combination therapy for all advanced renal cell carcinoma?
- Nivolumab plus ipilimumab versus sunitinib in first-line treatment for advanced renal cell carcinoma: extended follow-up of efficacy and safety results from a randomised phase 3 trial
- Targeted Therapies Following First-Line Immune Checkpoint Inhibitor Combination in Metastatic Renal Cell Carcinoma: A Single Center Experience
- Double Immune Checkpoint Blockade in Renal Cell Carcinoma
- Role of immune checkpoint inhibitor-based therapies for metastatic renal cell carcinoma in the first-line setting: A Bayesian network analysis
Related papers
- Nivolumab plus Ipilimumab versus Sunitinib in Advanced Renal-Cell Carcinoma
- Should we use combination therapy for all advanced renal cell carcinoma?
- [Risk Classification and Nivolumab plus Ipilimumab Combination Therapy for Treatment of Renal Cell Carcinoma].
- Two cases of anaphylaxis due to contrast media during administration of nivolumab and ipilimumab in metastatic renal cell carcinoma
- Nivolumab plus ipilimumab in advanced renal-cell carcinoma.
- Nivolumab–ipilimumab in renal cell carcinoma metastatic to the bones: A case report
- A Study of Combination Nivolumab and Ipilimumab Retreatment in Patients With Advanced Renal Cell Carcinoma
- Clinical and histological response to combination nivolumab and ipilimumab in metastatic renal cell carcinoma
- Study of Cabozantinib in Combination With Nivolumab and Ipilimumab in Patients With Previously Untreated Advanced or Metastatic Renal Cell Carcinoma
- An Immunotherapy Study of Nivolumab Plus Ipilimumab Versus Nivolumab Alone in Participants With Advanced Kidney Cancer